EOLS
Evolus, Inc.7.22
+0.08+1.12%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
468.00MP/E (TTM)
-Basic EPS (TTM)
-0.90Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Evolus names new CFO
Evolus appointed Tatjana Mitchell as Chief Financial Officer effective September 8, 2025, bringing her 20+ years of finance leadership from Experian and Zulily to drive revenue growth and operational scaling. She'll earn a $490,000 base salary, $100,000 signing bonus, 55% target annual incentive, and $1.5 million in equity grants vesting over four years. Mitchell joins as Evolus pushes profitability in aesthetics. Her expertise bolsters strategic execution amid market expansion risks.
8-K
Evolus Q2 revenue up 4%
Evolus reported Q2 2025 net revenue of $69.4 million, up 4% from last year despite softening U.S. toxin demand, fueled by $9.7 million from the blockbuster Evolysse launch and robust international sales. CEO David Moatazedi steps in as interim Principal Financial Officer on August 1, while CMO Tomoko Yamagishi-Dressler exits August 22 with severance. Cost cuts promise $25 million in non-GAAP savings; guidance resets to $295–$305 million revenue, targeting Q4 profitability. Tariffs loom, but impact stays minimal.
10-Q
Q2 FY2025 results: Revenues $69.4M (+3.7% YoY), driven by Evolysse™ launch. Net loss $17.1M vs $11.4M YoY. Cash $61.7M. Debt $145.5M. Reaffirmed FY25 revenue $295-305M.
Evolus, Inc. reported Q2 FY2025 results with net revenues of $69.4 million, up 3.7% YoY, driven by $9.7 million from Evolysse™ launch, offsetting Jeuveau® decline. Gross margin was 65.3%, down from 70.3% due to product mix. Operating expenses rose 13% to $56.7 million from Evolysse™ commercialization. Net loss was $17.1 million, up from $11.4 million YoY, with EPS at ($0.27) vs ($0.18). Cash was $61.7 million, down from $87.0 million, after $40.4 million operating cash use. Full-year revenue guidance reaffirmed at $295-305 million. Balance sheet showed $145.5 million debt, $18.7 million stockholders' deficit. No dividends planned. Risks include competition, regulatory issues, and economic factors.
IPO
Website
Employees
Sector
Industry
BHC
Bausch Health Companies Inc.
6.93+0.02
BIOE
Bio Essence Corp.
0.05+0.00
EBS
Emergent BioSolutions Inc.
12.19-0.14
EVH
Evolent Health, Inc
4.07-0.05
EVO
Evotec SE
3.01+0.03
EVOK
Evoke Pharma, Inc.
11.00+0.04
GALDY
GALDERMA GROUP AG
40.96-1.03
NSRX
Nasus Pharma Ltd.
6.80+0.00
SFWJ
Software Effective Solutions Co
0.00-0.00
ULTA
Ulta Beauty, Inc.
589.27-1.93